Grunenthal

News

Grünenthal's chief executive Gabriel Baertschi

Grünenthal buys Valinor and constipation drug for $250m

German pain medicines specialist Grünenthal has dipped another toe in the M&A waters with a $250 million agreement to buy US drugmaker Valinor Pharma.

News

Grünenthal’s non-opioid pain drug gets breakthrough tag

Grünenthal has been awarded a breakthrough designation from the FDA for its experimental painkiller resiniferatoxin, striving to become a treatment option that avoids the

News

Grünenthal buys into Kyowa Kirin's mature medicines portfoli...

German pharma Grünenthal has started the process of taking ownership of 13 ageing medicines developed by Japan's Kyowa Kirin, which are currently sold by affiliate companies across Europe.<

News

Grünenthal takes non-opioid pain drug resiniferatoxin into p...

Grünenthal has moved its painkiller resiniferatoxin into phase 3 trials in patients with osteoarthritis, hoping to find an option that sidesteps the side effects and addictive potential of

News

Bayer sells testosterone drug rights to Grünenthal for €500m

Bayer's venerable testosterone replacement product for men with hypogonadism – Nebido – is being sold to Grünenthal as the group continues a revamp of its healthcare business.